Zepbound Dosing for Obstructive Sleep Apnea
For adults with moderate-to-severe obstructive sleep apnea and obesity, start Zepbound (tirzepatide) at 2.5 mg subcutaneously once weekly, then titrate monthly to a maximum tolerated dose of 10 mg or 15 mg weekly over 52 weeks. 1
Dosing Algorithm
Starting dose: 2.5 mg subcutaneously once weekly
Titration schedule: Increase monthly by 2.5 mg increments as tolerated:
- Week 0-4: 2.5 mg weekly
- Week 5-8: 5 mg weekly
- Week 9-12: 7.5 mg weekly
- Week 13-16: 10 mg weekly
- Week 17+: 15 mg weekly (if tolerated)
Target maintenance dose: 10 mg or 15 mg weekly (maximum tolerated dose)
Treatment duration: 52 weeks minimum for OSA indication 1
Clinical Context
Tirzepatide received FDA approval in December 2024 as the first prescription medication specifically for moderate-to-severe OSA in adults with obesity 1. This represents a landmark indication, as the SURMOUNT-OSA trials demonstrated robust improvements in apnea-hypopnea index (AHI), with reductions of approximately 25-30 events per hour compared to 5-6 events per hour with placebo 2.
The dosing is identical whether patients are:
- Not using positive airway pressure (PAP) therapy
- Currently using PAP therapy 2
Both populations showed similar benefit, with estimated treatment differences of -20.0 events/hour (Trial 1, no PAP) and -23.8 events/hour (Trial 2, with PAP) 2.
Key Implementation Points
Slow titration is essential to minimize gastrointestinal side effects (nausea, vomiting), which are most common during dose escalation 1. Starting at the lowest dose (2.5 mg) and increasing monthly allows the body to acclimate to the medication.
If treatment is interrupted: Patients must restart at 2.5 mg and re-titrate upward, as tolerance is lost during treatment gaps 1.
Maximum tolerated dose varies: Not all patients will tolerate 15 mg. The approved maintenance doses are 5 mg, 10 mg, or 15 mg weekly, with 10-15 mg showing optimal efficacy 1.
Expected Outcomes
Beyond AHI reduction, tirzepatide at maximum tolerated doses produces:
- 18-25% body weight reduction 2
- Decreased hypoxic burden 2
- Reduced systolic blood pressure 2
- Improved sleep-related patient-reported outcomes 2
- Lower high-sensitivity C-reactive protein 2
These improvements occur across baseline characteristics including age, sex, BMI, AHI severity, and neck circumference 3.
Common Pitfalls
Avoid rapid titration: Jumping doses too quickly dramatically increases gastrointestinal adverse events and treatment discontinuation.
Monitor for dehydration: GI side effects (vomiting, diarrhea) can lead to dehydration and renal impairment, particularly during dose escalation 1.
Counsel on dietary modifications: Patients should avoid fatty foods, not eat past fullness, and consume smaller, more frequent meals to minimize nausea 1.
Watch for gallbladder disease: Weight loss from any modality increases gallbladder disease risk, and GLP-1 receptor agonists may augment this risk 1.